Bristol Myers shares fall 2.4% after fatal trial event
Key points
- Bristol Myers Squibb reported a fatal case of septic pneumonia following the data cutoff in an early-stage trial of its experimental cell therapy for multiple sclerosis.
- Shares fell 2.4% to $61.47, although the stock remained up 13.9% year to date, including the session's movements.
- The 66-patient trial evaluated zolacabtagene autoleucel in highly active relapsing multiple sclerosis, and the company said its overall safety profile remained consistent with previously reported data.
Bristol Myers Squibb (NYSE:BMY) shares fell 2.4% to $61.47 after the company disclosed a fatal septic pneumonia event reported after the data cutoff in an early-stage trial of its experimental multiple sclerosis therapy.
The trial enrolled 66 patients with highly active relapsing multiple sclerosis, an autoimmune disease that affects the central nervous system.
The fatal event involved septic pneumonia, a severe infection that can cause widespread inflammation and organ failure, and was reported after the trial's data cutoff.
The shares declined to $61.47 during the reported session, while the stock remained up 13.9% year to date, including the session's movements.
Bristol Myers Squibb develops medicines for cancer, immune-mediated diseases and other conditions, including investigational cell therapies designed to alter immune system activity.
